US Stock MarketDetailed Quotes
CLDX Celldex Therapeutics
- 35.380
- -1.540-4.17%
Close May 28 16:00 ET
- 35.700
- +0.320+0.90%
Post 16:32 ET
2.33BMarket Cap-12370P/E (TTM)
37.670High34.620Low1.06MVolume37.390Open36.920Pre Close37.52MTurnover1.61%Turnover RatioLossP/E (Static)65.91MShares53.18052wk High2.78P/B2.33BFloat Cap22.11052wk Low--Dividend TTM65.73MShs Float3374.997Historical High--Div YieldTTM8.26%Amplitude1.500Historical Low35.520Avg Price1Lot Size
Celldex Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -83.87%156K | 192.02%6.88M | 156.11%4.13M | 272.73%1.52M | 64.42%268K | 455.75%967K | -49.32%2.36M | 382.93%1.61M | 166.01%407K | -95.32%163K |
| Operating revenue | -83.87%156K | 192.02%6.88M | 156.11%4.13M | 272.73%1.52M | 64.42%268K | 455.75%967K | -49.32%2.36M | 382.93%1.61M | 166.01%407K | -95.32%163K |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | 21.91%40.76M | 36.06%148.93M | 33.09%39.26M | 52.14%42.76M | 20.04%33.47M | 39.52%33.44M | 48.31%109.45M | 41.01%29.5M | 45.03%28.1M | 67.36%27.89M |
| Selling and administrative expenses | 37.09%9.1M | 13.68%30.91M | 33.84%8.83M | 25.88%8.22M | 0.94%7.22M | -3.92%6.64M | 32.74%27.2M | 5.74%6.6M | 12.20%6.53M | 66.14%7.15M |
| -General and administrative expense | 37.09%9.1M | 13.68%30.91M | 33.84%8.83M | 25.88%8.22M | 0.94%7.22M | -3.92%6.64M | 32.74%27.2M | 5.74%6.6M | 12.20%6.53M | 66.14%7.15M |
| Research and development costs | 18.15%31.66M | 43.46%118.01M | 32.87%30.43M | 60.09%34.54M | 26.63%26.25M | 57.12%26.8M | 54.30%82.26M | 56.01%22.9M | 59.12%21.57M | 67.78%20.73M |
| Operating profit | -25.06%-40.61M | -32.63%-142.04M | -25.97%-35.13M | -48.90%-41.24M | -19.78%-33.21M | -36.47%-32.47M | -54.88%-107.1M | -35.46%-27.89M | -44.06%-27.7M | -110.30%-27.72M |
| Net non-operating interest income expense | ||||||||||
| Other net income (expense) | 150.80%7.8M | 111.72%613K | -685.05%-8.18M | 226.64%2.98M | 132.64%2.7M | 318.57%3.11M | -228.87%-5.23M | 219.91%1.4M | 162.72%912K | -4,236.13%-8.28M |
| Gain on sale of security | 150.80%7.8M | 350.77%13.11M | 209.08%4.32M | 226.64%2.98M | 589.54%2.7M | 1,402.42%3.11M | 476.04%2.91M | 628.13%1.4M | 528.97%912K | 485.07%392K |
| Special income (charges) | ---- | -53.60%-12.5M | ---12.5M | --0 | --0 | ---- | -288.45%-8.14M | --0 | --0 | -3,262.02%-8.67M |
| -Less：Restructuring and merger&acquisition | ---- | --0 | --0 | --0 | --0 | ---- | -388.40%-6.86M | --0 | --0 | -2,551.94%-6.33M |
| -Less:Impairment of capital assets | ---- | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- |
| -Less:Other special charges | ---- | -16.67%12.5M | ---- | ---- | ---- | ---- | --15M | --0 | ---- | --15M |
| Income before tax | -11.74%-32.81M | -25.91%-141.43M | -63.50%-43.31M | -42.85%-38.26M | 15.28%-30.5M | -27.38%-29.36M | -58.79%-112.33M | -31.46%-26.49M | -29.52%-26.78M | -169.23%-36M |
| Income tax | 0 | 0 | ||||||||
| Net income | -11.74%-32.81M | -25.91%-141.43M | -63.50%-43.31M | -42.85%-38.26M | 15.28%-30.5M | -27.38%-29.36M | -59.30%-112.33M | -31.46%-26.49M | -30.96%-26.78M | -169.23%-36M |
| Net income continuous Operations | -11.74%-32.81M | -25.91%-141.43M | -63.50%-43.31M | -42.85%-38.26M | 15.28%-30.5M | -27.38%-29.36M | -59.30%-112.33M | -31.46%-26.49M | -30.96%-26.78M | -169.23%-36M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | -11.74%-32.81M | -25.91%-141.43M | -63.50%-43.31M | -42.85%-38.26M | 15.28%-30.5M | -27.38%-29.36M | -59.30%-112.33M | -31.46%-26.49M | -30.96%-26.78M | -169.23%-36M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | -11.74%-32.81M | -25.91%-141.43M | -63.50%-43.31M | -42.85%-38.26M | 15.28%-30.5M | -27.38%-29.36M | -59.30%-112.33M | -31.46%-26.49M | -30.96%-26.78M | -169.23%-36M |
| Basic earnings per share | 9.68%-0.56 | -21.67%-2.92 | -50.00%-0.84 | -42.11%-0.81 | 15.58%-0.65 | -26.53%-0.62 | -46.34%-2.4 | -30.23%-0.56 | -26.67%-0.57 | -126.47%-0.77 |
| Diluted earnings per share | 9.68%-0.56 | -21.67%-2.92 | -50.00%-0.84 | -42.11%-0.81 | 15.58%-0.65 | -26.53%-0.62 | -46.34%-2.4 | -30.23%-0.56 | -26.67%-0.57 | -126.47%-0.77 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg